- Home
- TLPH vs PPBT Comparison
TLPH vs PPBT Comparison
Compare TLPH & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | PPBT |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 7.5M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLPH | PPBT |
|---|---|---|
| Price | $1.09 | $0.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 430.0K | ★ 779.9K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,267.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.53 |
| 52 Week High | $1.57 | $5.20 |
Technical Indicators
Market Signals| Indicator | TLPH | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 40.73 |
| Support Level | $1.20 | $0.72 |
| Resistance Level | $1.25 | $0.87 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 20.31 | 15.60 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.